Workflow
侵入式脑机接口开启临床,企业已收到上千名瘫痪患者请求
第一财经·2025-06-15 14:16

Core Viewpoint - China's invasive brain-computer interface (BCI) devices are rapidly entering clinical trials, marking a significant advancement in the field and positioning China as the second country globally to reach this stage after the United States [1][3]. Group 1: Clinical Trials and Developments - The first prospective clinical trial of invasive BCI in China has been successfully conducted by the Chinese Academy of Sciences and Fudan University, meeting medical device registration standards [1]. - Several companies, including Shanghai Ladder Medical Technology, are developing BCI devices aimed at treating patients with motor function disorders, such as spinal cord injuries and amyotrophic lateral sclerosis [3][4]. - Ladder Medical's BCI system has shown promising results, allowing patients to perform tasks like playing chess and racing games after just 2-3 weeks of training [3]. Group 2: Patient Recruitment and Research - The clinical cohort study led by Fudan University and Beijing Xuanwu Hospital has begun patient recruitment to validate the efficacy and safety of invasive BCI treatment [3]. - Companies like Beijing Chip Intelligence and Hangzhou Jialiang Medical have also announced plans for clinical research on BCI devices [3][4]. Group 3: Patient Impact and Demand - There is a significant demand for BCI technology, with over a thousand requests from paralyzed patients seeking participation in clinical trials [6][7]. - The development of BCI devices is seen as a beacon of hope for approximately 4 million spinal cord injury patients in China [7]. Group 4: Technological Advancements - Jialiang Medical has completed nearly 100 clinical implants for epilepsy treatment, with plans to submit data for product approval [8]. - Brain Tiger Technology has developed a next-generation wireless BCI product, which has shown capabilities in controlling complex games and smart devices [8]. Group 5: Industry Challenges and Future Outlook - Experts emphasize that while progress has been made, there is still a considerable gap between China's BCI development and that of leading global competitors [9]. - Companies are advised to focus on long-term research collaboration rather than immediate profit from BCI product sales [9].